It's only April, but we may have already witnessed the most costly clinical trial flopof 2018. Evaluate Pharmalisted Incyte Corporation's (NASDAQ: INCY)epacadostat as the third largest potential drug launch this year, and the first two are already on pharmacy shelves.
Is Beaten-Down Incyte Corporation Stock a Buy Now?
Понравилась статья? Подпишитесь на канал, чтобы быть в курсе самых интересных материалов
Подписаться